Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING
JIB
GLOBETECH PUBLISHING

European Biopharmaceutical Companies Launch Anticancer Drug Project

By BiotechDaily International staff writers
Posted on 12 Nov 2013
Two European biopharmaceutical companies are joining forces in an intensive effort to develop a new series of anticancer drugs.

ZoBio (Leiden, The Netherlands) will be applying its proprietary TINS technology to screen a library of drug fragments for specific binding to the desired conformation of the target protein.

TINS is a powerful approach that has been validated on a wide range of targets including viral proteins, proteases, kinases, protein-protein interaction targets, molecular chaperones, and membrane proteins. TINS uses a single sample of the target and a reference protein that have been immobilized on Sepharose-based resin. Fragments to be assayed for binding are injected as mixtures of between three and nine compounds. Binding is detected by a reduction in the height of the NMR signals of a compound that specifically binds to the target. Comparison of the NMR spectra of the fragments in the presence of the target and reference proteins directly reveals the identity of the binding ligand.

ZoBio offers its proprietary TINS technology for ligand screening studies on its own, highly validated fragment library or the customer’s. A typical TINS discovery and characterization/validation project is completed in one to two months.

ZoBio's partner in the new project is Actelion Ltd. (Allschwil, Switzerland), a company that has demonstrated global leadership in the field of pulmonary arterial hypertension (PAH) therapy. Actelion is known for a strong and effective worldwide specialty commercial organization, a highly productive discovery capability, and a unique company culture that focuses on delivering innovative medicines that improve patient’s lives.

Dr. Gregg Siegal, CSO of ZoBio said, “We are proud that Actelion, a company with such success in bringing innovative drugs to the market, has selected ZoBio as a partner. We feel that this collaboration has a great chance to succeed where others have failed.”

Related Links:

ZoBio
Actelion Ltd.



comments powered by Disqus

Channels

Genomics/Proteomics

view channel
Image: Alternative splicing produces two protein isoforms (Photo courtesy of Wikimedia Commons).

Key Regulator of Cancer-Inducing Alternative Splicing Identified

Cancer researchers have identified the splicing factor RBM4 (RNA-binding protein 4) as a key determinant in processes that prevent tumor development and spread. RBM4 is known to be crucial to gene splicing... Read more

Therapeutics

view channel
Image: Hair follicle (blue) being attacked by T cells (green) (Photo courtesy of Christiano Lab/Columbia University Medical Center).

Hair Restoration Method Clones Patients’ Cells to Grow New Hair Follicles

Researchers have developed of a new hair restoration approach that uses a patient’s cells to grow new hair follicles. In addition, the [US] Food and Drugs Administration (FDA) recently approved a new drug... Read more

Lab Technologies

view channel
Image: Leica Microsystems launches the inverted research microscope platform Leica DMi8 (Photo courtesy of Leica Microsystems).

New Inverted Microscope Designed to Readily Adapt to Changing Research Demands

A new inverted microscope for biotech and other life science laboratories was designed to readily accommodate modifications and upgrades to allow it to keep current with changing research demands and interests.... Read more

Business

view channel

Partnership Established to Decode Bowel Disease

23andMe (Mountain View, CA,USA), a personal genetics company, is collaborating with Pfizer, Inc. (New York, NY, USA), in which the companies will seek to enroll 10,000 people with inflammatory bowel disease (IBD) in a research project designed to explore the genetic factors associated with the onset, progression, severity,... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.